Rx Product Updates (April 2017)

SPIRIVA RESPIMAT

Marketed by:

Boehringer Ingelheim

Indication:

The FDA has expanded the indicated for the approved Spiriva Respimat (tiotropium bromide) for the long-term, once-daily maintenance treatment of asthma in individuals 6 years and older.

Dosage form:

Oral inhalation: 1.25 mcg

For more information: spiriva.com

PARSABIV

Marketed by:

Amgen

Indication:

The FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on hemodialysis.

Dosage form:

Injection: 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL

For more information: amgen.com

TRULICITY

Marketed by:

Eli Lilly

Indication:

The FDA approved Eli Lilly’s updated label for its type 2 diabetes drug, Trulicity (dulaglutide), to include use in combination with basal insulin for adults with type 2 diabetes. The FDA included the changes to the approved product labeling to reflect this important information for prescribers.

Dosage form:

Injection: 0.75 and 1.5 mg

For more information: trulicity.com